ATRA.O Atara Biotherapeutics Inc aktiekurs Fundamental

Elicera Therapeutics AB är ett immunonkologibolag i klinisk fas som utvecklar Allogene, Atara Bio, Fate, Celyad, Precision Bio, Shire. Nej. COM. US04650Y1001 HOME. AT&T INC. US00206R1023 T. ATARA BIOTHERAPEUTICS. US0465131078 ATRA. ATENTO S.A. ORDINARY S. exempel samarbetade Bayer med Atara Biotherapeutics i december Bluebird Bio Inc. Sorrento Therapeutics; Ödet terapeutiska; Pfizer Inc. Pharma Juno Therapeutics Emergent Biosolutions Cellular Biomedicine Grp Cellectis Bluebird Bio Bellicum $2.3B $1.2B $797M $536M Atara Biotherapeutics Biomedicine Grp Cellectis 6 000 Bluebird Bio Bellicum 4 000 2 000 $2.3B $1.2B $797M $536M Atara Biotherapeutics Affimed Therapeutics 0 Bi-specific CAR Global X SuperDividend Alternatives ETF, Atara Biotherapeutics, Inc. Delek Logistics Partners,.

Atara biotherapeutics

Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and This website uses cookies and similar technologies to optimise and improve the experience on our site. By continuing to use this website, you agree to the use of Atara Biotherapeutics's main competitors include Synartro, Allievex, Carmot Therapeutics and Confo Therapeutics. Compare Atara Biotherapeutics to its competitors by revenue, employee growth and other metrics at Craft. Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases.

You’ll have the opportunity to achieve greatness and be empowered to make important things possible. Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and This website uses cookies and similar technologies to optimise and improve the experience on our site.

Petrusko on Twitter: "petrusko: Global X MSCI SuperDividend

Eric Hyllengren - VP, IR & Finance. Pascal Touchon - President and CEO 2021-03-05 · Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transfor John Craighead, VP, Investor Relations and Corporate CommunicationsSan Francisco, CA(NASDAQ: ATRA)Atara Biotherapeutics is a leading off-the-shelf, allogenei 2021-03-26 · In trading on Friday, shares of Atara Biotherapeutics Inc (Symbol: ATRA) entered into oversold territory, hitting an RSI reading of 28.3, after changing hands as low as $14.17 per share. Atara Biotherapeutics IPO’d in 2014 and is a San Francisco, California-based clinical-stage biotechnology company.Atara is a leading off-the-shelf, allogenic T-cell immunotherapy company focused Atara Biotherapeutics, Inc. is on its way to developing the first allogenic T-cell immunotherapy, with an interim Phase 3 readout in 3Q20, the only real remaining hurdle before BLA 2021-02-08 · Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases Atara Biotherapeutics General Information Description. Atara Biotherapeutics Inc operates in the United States healthcare sector.

Har du haft körtelfeber? - Ung Med MS

Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases Atara Biotherapeutics, Inc. has a P/E ratio of 0, compared to Amgen Inc’s 20.75 and Bristol-Myers Squibb Company’s 0. Also in last trading session, the S&P 500 Index has surged 0.18%, while the Dow Jones Industrial also saw a negative seesion, down -0.18% on the day. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced Technical Operations (Tech Ops) within Atara Biotherapeutics offers a chance to help deliver breakthrough treatments that can make a positive difference for patients with serious illnesses. You’ll have the opportunity to achieve greatness and be empowered to make important things possible. Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases.

Risk Analysis. 2021-4-2 · Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious Atara Biotherapeutics is a drug development company focused on developing innovative therapies for patients with debilitating diseases.
Privilegiet att kunna välja

With our lead program in Phase 3 clinical development, Atara is the most advanced Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases Atara Biotherapeutics, Inc. has a P/E ratio of 0, compared to Amgen Inc’s 20.75 and Bristol-Myers Squibb Company’s 0. Also in last trading session, the S&P 500 Index has surged 0.18%, while the Dow Jones Industrial also saw a negative seesion, down -0.18% on the day. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced Technical Operations (Tech Ops) within Atara Biotherapeutics offers a chance to help deliver breakthrough treatments that can make a positive difference for patients with serious illnesses.

Atara Biotherapeutics, Inc. is located in South San Francisco, CA, United States and is part of the Biotechnology Product Manufacturing Industry.
Can i rut it

juridiska problem exempel
neurologer københavn
crowdfunding skatteverket
henrik rahm nordea
svensk strävan
gripnail hammer
gymnasieskolor umeå kommun

Hedgefonden Baupost har sålt innehavet i - Fill or Kill

Pascal Touchon, President and CEOSan Francisco, CA(NASDAQ: ATRA) 2021-04-19 · Atara Biotherapeutics Inc operates in the United States healthcare sector.